These include lack of effects on targets important for cardiovascular and cerebrovascular diseases (eg. muscarinic receptors, 5-hydroxytryptamine receptor 1B), heart disease (eg. phosphodiesterase 3 inhibitors, 5-hydroxytryptamine receptor 2B), psychiatric and neurodegenerative disorders (eg. monoamine oxidase inhibitors, dopamine receptors), endocrine diseases (eg. androgen receptor), asthma and chronic obstructive pulmonary disease (eg. histamine H receptor), as well as those important for drug safety, including a lack of binding to the drug-induced long QT syndrome associated hERG1. This evidence concerns the gene HTR1B and heart disorder.